Enrofloxacin Use in Avian Medicine: Indications and Withdrawal Periods

Enrofloxacin is a synthetic fluoroquinolone antimicrobial agent that has been extensively employed in avian medicine for the treatment of systemic bacterial infections [1]. This article provides a detailed examination of its pharmacological properties, approved indications in poultry and companion birds, recommended dosage regimens, mandated tissue and egg withdrawal periods, and the emerging challenges of antimicrobial resistance in avian pathogens.

Fluoroquinolone Pharmacology

Enrofloxacin belongs to the second-generation fluoroquinolone class and exerts its bactericidal effect by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes critical for DNA replication, transcription, and repair [1, 2]. The drug demonstrates concentration-dependent killing and a significant post-antibiotic effect against susceptible Gram-negative and Gram-positive organisms [1]. In avian species, enrofloxacin is rapidly absorbed after oral administration and undergoes partial hepatic de-ethylation to its active metabolite ciprofloxacin, which contributes to overall antimicrobial activity [2].

Approved Indications in Poultry

The primary approved indications for enrofloxacin use in poultry include infections caused by susceptible strains of Escherichia coli, Pasteurella multocida, Mycoplasma gallisepticum, Mycoplasma synoviae, and Salmonella species, as detailed in standard references [3, 4]. These indications encompass a range of disease conditions commonly encountered in commercial poultry production.

Colibacillosis

Avian pathogenic Escherichia coli (APEC) causes colibacillosis, a multifactorial disease characterized by airsacculitis, pericarditis, perihepatitis, and septicemia [3]. Enrofloxacin is indicated for the treatment of colibacillosis in broilers, layers, and turkeys, particularly when in vitro susceptibility is confirmed [1, 3]. The drug provides rapid clinical improvement when administered early in the course of infection. This condition is discussed in greater detail in the article on Avian Colibacillosis: Pathogenesis, Diagnosis, and Antimicrobial Resistance Patterns in Poultry.

Fowl Cholera

Fowl cholera, caused by Pasteurella multocida, is a highly contagious disease of chickens, turkeys, and waterfowl [4]. Enrofloxacin is used for the control of acute septicemic outbreaks, particularly when other antimicrobial classes have failed due to resistance [1, 4]. Detailed clinical management of fowl cholera is covered in Avian Cholera (Fowl Cholera): Etiology, Pathogenesis, and Control.

Mycoplasmosis

Mycoplasma infections, especially M. gallisepticum and M. synoviae, are economically significant in chicken and turkey flocks [5]. Enrofloxacin is effective in reducing clinical signs and vertical transmission, although its ability to eliminate the organism from carrier birds is limited [1, 5]. The article on Avian Mycoplasmosis in Poultry: Clinical Signs and Control provides additional context.

Salmonellosis

Enrofloxacin is sometimes used for the treatment of systemic salmonellosis in poultry, including infections caused by Salmonella enterica serovars such as Salmonella enteritidis and Salmonella typhimurium [3, 6]. However, because of public health concerns regarding fluoroquinolone resistance in zoonotic Salmonella, its use is restricted or prohibited in many countries for food-producing animals [6]. Readers can refer to Salmonellosis in Poultry: Comprehensive Guide to Salmonella in Chickens for further information.

Avian Enrofloxacin Use in Companion and Non-Commercial Birds

Beyond poultry, enrofloxacin is widely used in psittacine birds (parrots, cockatiels), passerines, and raptors for the treatment of Gram-negative infections, including those caused by Pseudomonas aeruginosa, Klebsiella pneumoniae, and Enterobacter species [2, 7]. It is also employed in the management of Avian Chlamydiosis (Psittacosis) in Pet Birds caused by Chlamydia psittaci, although doxycycline remains the first-line agent [7]. Dosage forms include injectable solutions for intramuscular or subcutaneous administration and oral suspension formulations [2].

Dosage Regimens

Dosage recommendations for enrofloxacin in avian species vary according to the target species, route of administration, and indication. Table 1 summarizes commonly cited dosages from standard veterinary pharmacology references [1, 2].

Table 1. Enrofloxacin dosage guidelines in avian species

These dosages represent general guidelines; actual dosing should be based on body weight, severity of infection, and local regulatory approvals [1, 2]. In food-producing birds, enrofloxacin administration must adhere to extra-label drug use regulations where applicable, and a valid veterinarian-client-patient relationship is required [1, 3].

Withdrawal Periods

Withdrawal periods for enrofloxacin in poultry are established to ensure that residues in edible tissues and eggs fall below established maximum residue limits (MRLs) at the time of slaughter or collection [8]. The withdrawal time is influenced by the drug formulation, dosing regimen, and species.

Tissue Withdrawal

In broiler chickens, a minimum withdrawal period of 7 days after oral treatment is typically recommended before slaughter for human consumption [1, 8]. For turkeys, the withdrawal period is commonly extended to 12 days due to slower drug clearance in this species [1, 8]. These values reflect the time required for residues to deplete below the MRL for enrofloxacin, which is set by regulatory agencies such as the European Medicines Agency and the U.S. Food and Drug Administration [8].

Egg Withdrawal

Enrofloxacin is not approved for use in laying hens in many jurisdictions because residues concentrate in eggs and can persist for an extended duration [8]. Where extra-label use is permitted, an egg withdrawal period of at least 9 to 14 days is often cited, but this may be insufficient to guarantee zero residue [1, 8]. Therefore, treatment of laying flocks with enrofloxacin is discouraged, and treated hens should not have eggs marketed for human consumption during the withdrawal period [8].

Antimicrobial Resistance Concerns

The use of enrofloxacin in poultry has been associated with the emergence and dissemination of fluoroquinolone resistance in commensal and pathogenic bacteria [3, 6]. Resistance mechanisms include chromosomal mutations in the quinolone resistance-determining regions (QRDR) of DNA gyrase and topoisomerase IV, as well as plasmid-mediated quinolone resistance (PMQR) genes such as qnr [6].

Of particular concern is the selection of fluoroquinolone-resistant Salmonella serovars and Campylobacter species, which can be transmitted to humans through the food chain [6]. Some countries have therefore banned or restricted the use of enrofloxacin in poultry to mitigate this risk [3, 6]. In regions where use remains legal, routine susceptibility testing is critical to guide appropriate therapy and preserve the efficacy of fluoroquinolones [1, 3].

Decision Workflow for Enrofloxacin Use in Avian Medicine

The following Mermaid diagram outlines a clinical decision pathway for considering enrofloxacin therapy in a poultry flock.

graph TD
    A[Clinical suspicion of bacterial disease], > B[Collect specimens for culture and susceptibility]
    B, > C{Diagnosis confirmed?}
    C, Yes, > D{Isolate susceptible to enrofloxacin?}
    C, No, > E[Consider alternative or symptomatic therapy]
    D, Yes, > F{Is the species and production type permitted?}
    D, No, > G[Select alternative antimicrobial]
    F, Yes, > H[Administer enrofloxacin per label or extra-label protocol]
    F, No, > I[Enrofloxacin not approved for this class; seek alternatives]
    H, > J[Record treatment date and dose]
    J, > K[Observe mandated tissue/egg withdrawal period]
    K, > L[Confirm clearance via residue testing if required]
    L, > M[Slaughter or market products]

This workflow emphasizes the importance of laboratory confirmation, susceptibility testing, and compliance with withdrawal periods to ensure both therapeutic success and food safety [1, 3, 8].

Concluding Remarks

Enrofloxacin remains an important therapeutic option for selected bacterial infections in avian species, including poultry and companion birds. Its use must be guided by antimicrobial susceptibility patterns, adherence to label or extra-label dosage regimens, and strict observation of withdrawal times to prevent harmful residues in food products and to slow the development of resistance. Growing regulatory restrictions reflect a global commitment to antimicrobial stewardship in veterinary medicine.

References

[1] Plumb DC. Plumb's Veterinary Drug Handbook. 9th ed. Wiley-Blackwell.

[2] Carpenter JW. Exotic Animal Formulary. 5th ed. Elsevier.

[3] Swayne DE, Glisson JR, McDougald LR, Nolan LK, Suarez DL, Nair V, editors. Diseases of Poultry. 14th ed. Wiley-Blackwell.

[4] Glisson JR. Fowl cholera. In: Merck Veterinary Manual. 11th ed. Merck & Co.

[5] Kleven SH. Mycoplasmosis. In: Merck Veterinary Manual. 11th ed. Merck & Co.

[6] World Health Organization. Critically Important Antimicrobials for Human Medicine. 6th revision. Geneva: WHO.

[7] Speer BL. Psittacine therapeutics. In: Current Therapy in Avian Medicine and Surgery. Elsevier.

[8] European Medicines Agency. Committee for Medicinal Products for Veterinary Use: Enrofloxacin. EMA/CVMP. *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.